



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com **Website :** www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/65

Date: 19th February 2025

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Intimation for Board approval for incorporating a Limited Liability Company in Poland as a wholly-owned Subsidiary of the Company
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have approved to incorporate a Limited Liability Company in Poland, which will be a wholly-owned subsidiary of the Company. The Company will subscribe 100 shares of Polish złoty 50 each (currency of Poland 'PLN') of the proposed-Company aggregating to PLN 5,000 (approx. Rs.1,50,000/-) equivalent to 100.00% of the paid up share capital of the proposed-Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited


Sachin Mehta
Joint Managing Director &
Chief Financial Officer

Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com **Website :** www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) **CIN :** L51496MH2008PLC184997

Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

Sl. No.	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	Name: Sudarshan Pharma Poland Limited Liability Company (proposed-Company)
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	To carry on business of processing and preserving potatoes and to carry out production of basic organic and inorganic chemicals, fertilizers and nitrogen compounds, pesticides, disinfectants and other agrochemicals, soap and detergents, washing and cleaning agents, basic pharmaceutical substances, medicines and other pharmaceutical products and other chemical products and to act as wholesalers of perfumes, cosmetics, pharmaceutical and medical products.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The incorporation of Sudarshan Pharma Poland LLC will allow the Company to establish a place of business in the Republic of Poland.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route).
6	Indicative time period for completion of the incorporation	30 th April, 2025



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com **Website :** www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) **CIN :** L51496MH2008PLC184997

7	Nature of Consideration whether Cash consideration or share swap and details of the same	Consideration for acquiring shares of Sudarshan Pharma Poland to be done in cash.
8	Cost of acquisition or the price at which the shares are acquired.	Not exceeding Rs.1,50,000/- only (Rupees One Lakhs Fifty Thousand only) or its equivalent in Polish Zloty.
9	Percentage of shareholding control acquired and / or number of shares acquired	100 shares of PLN 50/- each (100.00% of the paid-up share capital) of Sudarshan Pharma Poland LLC from the following shareholders: 1. Sudarshan Pharma Industries Limited (100%)
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable as Sudarshan Pharma Poland LLC is not yet incorporated.

For, Sudarshan Pharma Industries Limited


Sachin Mehta
Joint Managing Director &
Chief Financial Officer